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Abstract: We applied 13C magnetic resonance spectroscopy (MRS), a nonradioactive, nonin-
vasive brain imaging technique, to quantify the oxidation of [1-13C] acetate in a conventional 
clinical magnetic resonance imaging (MRI) scanner in five consecutive elderly subjects at various 
clinical stages of Alzheimer’s disease (AD) progression. [1-13C] acetate entered the brain and 
was metabolized to [5-13C] glutamate and glutamine, as well as [1-13C] glutamate and glutamine, 
and the final glial oxidation product, 13C bicarbonate, at a linear rate. Calculation of the initial 
slope was similar in a single subject, examined twice, 1 month apart (test-re-test 8%). Mean rate 
of cerebral bicarbonate production in this elderly group was 0.040 ± 0.01 (n = 5). Assuming that 
the rate of conversion of acetate to bicarbonate is a reflection of glial metabolic rate and that glial 
metabolic rate is a surrogate marker for ‘neuroinflammation’, our preliminary results suggest 
that [1-13C] MRS may provide biomarkers for diseases, believed to involve microglia and other 
cells of the astrocyte series. Among these is AD, for which novel drugs which ameliorate the 
damaging effects of neuroinflammation before symptoms of dementia appear, are in advanced 
development. The value of 13C MRS as an early, noninvasive biomarker may lie in the conduct 
of cost-effective clinical trials.
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Introduction
In Alzheimer’s disease (AD), incidence and prevalence increase with age. AD is the sixth 
leading cause of death in the US, and there are no effective therapies for the disease. 
Development of disease-modifying treatments for AD has been both expensive and 
unsuccessful to date. A shortcoming of current largely neuronal biomarkers, magnetic 
resonance imaging (MRI), amyloid imaging, and cerebrospinal fluid biomarkers, is 
the absence of an accepted biomarker for glial activation.1,2 Neuroinflammation, also 
termed glial activation, has long been implicated in the pathology of AD.3 Recent 
research has shown that there are early pathological changes in the brains of persons 
with predementia memory decline, which can even be detected in asymptomatic 
individuals who may eventually develop AD.4,5 This phenomenon occurs early in the 
course of AD possibly before the more extensive neuron damage monitored by clinical 
tests. Most AD clinical trials depend on measures of rates of change in highly variable 
and insensitive clinical and cognitive measures. Therefore, there is an urgent need for 
appropriate biomarkers that can serve as outcome endpoints to detect progression of 
disease.
Magnetic resonance spectroscopy (MRS) is a powerful method for measuring brain 
metabolism. Noninvasive proton MRS has been used to measure brain chemical contents Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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statically6–8 while minimally invasive carbon MRS has been used 
to measure brain metabolic processes in action, dynamically.9 
With appropriate infusion of brain exogenous labeled sub-
strates, neuronal and glial metabolic rates have been reported 
in numerous neurodegenerative diseases.10–14 It is accepted that 
acetate, which enters the brain tricarboxylic acid cycle via an 
astrocyte-specific enzyme, can be used as a tracer for astrocyte 
or glial oxidative metabolism.15–17 Both C1 and C2 labeled 
acetate have been used successfully to study glial metabolism in 
intact human brains.10,13,14 In aging, evidence of upregulation of 
astrocytes (glia) metabolism was demonstrated with an increase 
of 25% in older subjects compared with younger adults using 
labeled C2 acetate as exogenous substrate.18
In this preliminary communication, we employed a short 
protocol developed previously19 to directly measure glial 
dysfunction in Alzheimer’s patients using C1 acetate as an 
exogenous labeled substrate.
Methods
Patients
The studies were approved by the local internal review 
board (Huntington Memorial Hospital), and all patients 
gave written informed consent. A total of 24 MRI/MRS 
studies were performed on six subjects of whom two had 
AD, two had mild cognitive impairment (MCI) and two were 
healthy older adults with mean age of 78 ± 3 years, and two 
were females.
Neuropsychological assessments
All subjects underwent extensive neuropsychological 
evaluation using the standard test battery to evaluate AD.20 
Briefly: premorbid estimates of intellectual functioning 
were performed (Wechsler Test of Adult Reading). The 
core neuropsychological battery included the Wechsler 
Adult Intelligence Scales, third ed. (WAIS-III) and the 
Wechsler Memory Scales, third ed. (WMS-III) Domains 
of Attention/Concentration/Working Memory (WAIS-III 
Digit Span, Letter–Number Sequencing and Arithmetic), 
Psychomotor/Information processing (WAIS-III Symbol 
Search and Digit Symbol, Stroop word reading and color 
naming), Language functions (COWAT-FAS and Animals, 
WAIS-III Information), Verbal Memory (WMS-III Logical 
Memory I and II, California Verbal Learning Test-II), 
Nonverbal Memory (Brief Visual Memory Test-Revised, 
Rey Osterreich Complex Figure Test-Delay), Visuospatial/
construction (WAIS-III Block Design, Picture Completion, 
Ruff Figural Fluency, Judgment of Line Orientation, Rey 
Osterreich Complex Figure Test-Copy) Executive Functions 
Table 1 Compilations of subjects’ characteristics, proton, carbon MRS, and neuropsychological assessment results
Patient 1  
Control
Patient 2  
Control
Patient 3  
MCI
Patient 4  
MCI
Patient 5  
AD
Patient 6   
AD
Subject characteristics
Age 80 83 77 81 76 76
Gender M M M M F F
MMSE 30 28 26 27 22 22
Proton MRS results
NAA/Cr 1.45 1.37 1.47 1.37 1.62 1.39
mi/Cr 0.56 0.72 0.77 0.74 0.85 0.83
NAA/mi 2.6 1.92 1.92 1.85 1.34 1.67
Carbon MRS results
Rate of bicarbonate 
production (%FE/minute)
0.023 0.03 0.042 0.033 0.056 0.06
Neuropsychological assessment (Z scores)
Attention/concentration 
Working memory
WNL WNL –2 WNL −1.6 −1.6
Psychomotor/ 
information processing
WNL WNL WNL WNL −1.5 −1.5
Language functions WNL WNL –1.5 WNL −1.5 −1.5
Verbal memory WNL WNL –1.3 –1.3 −3 −3
Nonverbal memory WNL WNL –3 WNL –3 −3
Visuospatial/ 
construction
WNL –1.4 –1.4 –2 −2 −2
Executive functions WNL –1.4 –2.5 WN: −3 −3
Motor functions WNL WNL –1.3 WNL WNL WNL
Abbreviations: AD, Alzheimer’s disease; Cr, creatine; FE, fractional enrichment; mi, myo-inositol; MCi, mild cognitive impairment; MMSE, mini-mental state examination; 
MRS, magnetic resonance spectroscopy; NAA, N-acetyl aspartate; WNL, within normal range.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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(Delis–Kaplan Executive Functions System – Tower Test), 
and Motor Functioning (Purdue Pegboard) were assessed.
All subjects underwent mini-mental state examination 
(MMSE). Criteria for MCI cut-off from normal included 
absence of dementia (MMSE $ 23) essentially preserved 
activities of daily living, the presence of cognitive and/or 
memory complaints, and impairment .1 standard devia-
tion below age norms on one or more immediate or delayed 
memory tests or $2 nonmemory tests.21 Criteria for AD 
classification included MMSE score ,23, impairment in 
activities of daily living, and $2 standard deviations below 
age norms on a majority of memory tests.
Neuroimaging and spectroscopy
Examinations were performed on a GE 1.5 T MRI scanner 
equipped with non-proton MRS capability as previously 
prescribed.22 Localized MRI was acquired with a 30-slice 
T2-weighted fast spin echo imaging sequence with echo time 
(TE) = 96 milliseconds, repetition time (TR) = 4 seconds, slice 
thickness = 5 mm, 1 excitation, and 256 × 192 data acquisition 
matrix using a single channel quadrature head coil for both 
transmitting and receiving. These localizer images were used 
to prescribe two single voxel proton MRS acquisitions of 
posterior cingulate grey matter and white matter (PROBE-p 
TE = 35 milliseconds, TR = 1.5 seconds, 8 mL voxel, 128 
averages). For proton decoupled 13C MRS, scanning protocol 
is similar to that previously described.19,23 Briefly, prior to the 
start of the infusion protocol, a natural abundance 13C MRS was 
acquired for 30 minutes of five blocks pulse, to acquire data 
averaging a Waltz-4 bi-level proton decoupling and nuclear 
OverHouser (NOE) scheme with a power level of 5 W during 
decoupling and 0.9 W during the NOE period. Subsequently, 
intravenous administration of stable isotope enriched 1–13C 
acetate (Cambridge Isotopes Laboratories, Andover, MA; FDA 
IND 59,950) was performed with the subjects lying comfort-
ably outside the MRI scanner for 60 minutes. The patients 
were then swiftly positioned back in the MRI scanner and data 
acquisition was performed for another 60 minutes.
Data and statistical analysis
Automated spectral processing for single voxel proton 
MRS data was performed using the commercially available 
LCModel software24 using a standard 1.5T reference basis 
set for semi-quantification. The results are reported as meta-
bolic ratios.
For 13C MRS time series data were processed as previ-
ously described using an observer-independent automatic 
IDL-based software developed in house and SAGE (GE 
Healthcare, Milwaukee, WI).14 The rate of bicarbonate 
production was determined using the difference between 
the amount of measured bicarbonate level pre- and post-
infusion over the time from the start of infusion to the end 
of data acquisition.19
Simple statistical analysis was performed using linear 
regression, and the goodness of linear fit is reported as R2.
Results
Subject characteristics, MRS, and neuropsychological 
evaluation results are shown in Table 1.
Proton MRS shows increased myoinositol to creatine 
ratio and decreased N-acetyl aspartate to myoinositol ratio, 
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Figure 1 Proton MRS spectra from healthy elderly (A), an elderly subject with MCi (B) and an AD patient (C). Spectra were scaled to creatine peak intensity.
Abbreviations: AD, Alzheimer’s disease; MCi, mild cognitive impairment; mi, myo-inositol; MRS, magnetic resonance spectroscopy; NAA, N-acetyl aspartate.
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Figure 2 Typical spectra (147–167 ppm region) of 13C MRS in an AD subject at 
baseline (A) and at 1 hour after start of infusion (B).
Abbreviations: MRS, magnetic resonance spectroscopy; AD, Alzheimer’s disease; 
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similar to results previously reported.5 Typical proton MRS 
spectra in cognitively normal, MCI, and AD subjects are 
shown in Figure 1.
Glial metabolism of  13C acetate was demonstrated by 
increased  13C enrichment of cerebral bicarbonate (HCO3, 
161 ppm) compared with pre-infusion (Figure 2). The unenriched 
total creatine resonance (tCr, 158 ppm) was also observed.
Clinically defined normal, MCI, and AD patients (MMSE 
normal = 28–30, MCI = 23–27, AD < 23) was accompanied by 
reduction in NAA/mI (−36% ± 0.05; P = 0.01) as previously 
described.5
In contrast, 13C MRS showed a progressive increase in 
enrichment of the glial-oxidation product, 13C-bicarbonate 
(Figure 2). The increase in glial metabolic activity showed 
that %fractional enrichment of bicarbonate was inversely 
  correlated with clinical grade (MMSE) (R2 = 0.908) 
(Figure 3A) and MRS-glial biomarker (mI/Cr) (R2 = 0.753) 
(Figure 3B). Weak or no correlation was observed for 
neuronal biomarker (NAA/Cr) and glial metabolic activity 
(R2 = 0.11) (not shown).
Conclusions
Our preliminary results directly demonstrate progressively 
elevated glial metabolic rate in patients with MCI and AD 
in proportion to the elevation in glial marker myoinositol of 
conventional proton MRS, and inversely correlated with a 
clinical measure of cognitive decline, MMSE. Although the 
number of patients in this preliminary study is small, the data 
could contribute to the ongoing debate supporting the general 
belief that activation of glia observed in animal models, may 
occur in human MCI and AD.
Neuroscientists have made extensive use of the term 
‘neuroinflammation’ to describe a complex process that 
occurs when glia cells undergo activation in response to 
stimuli such as viral infection,25,26 undesirable substances,27,28 
injury,29 and illnesses.30 Activated microglia and glia 
cells have been reported in AD.3,31,32 It is possible that our 
observation of an increase in glial activation is synonymous 
with neuroinflammation. Additional studies are required 
to confirm that relationship. If confirmed, 13C MRS after 
infusion of 1–13C acetate as employed here would provide a 
practical approach to defining neuroinflammation in human 
brain. Extending the present observation to larger numbers 
of well-defined patients and in longitudinal studies which 
document the onset of glial hyperactivity in comparison with 
the earliest evidence of neuronal loss (proton MRS or 13C 
MRS using 1–13C glucose as exogenous substrate are valid 
techniques33) could provide direct information on whether 
neuroinflammation is the immediate cause of MCI and AD 
or merely a secondary effect of neuronal injury. A conclusion 
in favor of the former mechanism would support the renewed 
impetus for preventative therapies, which target neuroinflam-
mation in the increasing numbers of patients diagnosed with 
early AD. Human use of 13C MRS, as demonstrated here, is 
a safe, nonradioactive technique which can be performed on 
conventional clinical MRI scanners with only minor modifica-
tion, and would be a valuable tool for such future studies.
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